NFG
VIRX

Noven Financial Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Noven Financial Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-195
Closed -$23K – 41
2016
Q2 		$23K Hold
195
– – 0.02% 38
2016
Q1 		$22K Hold
195
– – 0.02% 41
2015
Q4 		$37K Buy
195
+71
+57% +$13.3K 0.03% 39
2015
Q3 		$21K Buy
+124
New +$44.7K 0.02% 36

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Noven Financial Group's VIRX Position: Q3 2016 in Review

Noven Financial Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 195 shares — an estimated $23K sold.

Noven Financial Group first reported a position in VIRX in Q3 2015 and held it in 4 quarters. The position peaked at $37K in Q4 2015. 39 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

  • Noven Financial Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Noven Financial Group sold 195 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $23K.
  • Noven Financial Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
  • Noven Financial Group's Viracta Therapeutics, Inc. Common Stock position peaked at $37K in Q4 2015.
  • 39 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Noven Financial Group's 13F filing for Q3 2016, filed 14 Nov 2016.